NASDAQ:PRLD | Free Cash Flow | Prelude Therapeutics Inc

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$21.69M$0.00-$21.69M
2025-12-31$23.12M$0.00$23.12M
2025-03-31-$34.23M$47,000.00-$34.28M
2024-12-31-$20.74M$53,000.00-$20.8M
2024-03-31-$31.79M$289,000.00-$32.08M
2023-12-31-$23.58M$1.13M-$24.71M
2023-03-31-$30.13M$810,000.00-$30.94M
2022-12-31-$22.93M$393,000.00-$23.32M
2022-03-31-$21.9M$952,000.00-$22.85M
2021-12-31-$25.7M$297,000.00-$26M
2021-03-31-$16.14M$986,000.00-$17.13M
2020-12-31-$14.85M$329,000.00-$15.18M
2020-03-31-$9.92M$80,000.00-$10M
2019-12-31-$8.47M$199,000.00-$8.67M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$56.3M$67,000.00-$56.37M
2024-12-31-$102.89M$764,000.00-$103.65M
2023-12-31-$107.06M$3.51M-$110.58M
2022-12-31-$83.73M$3.02M-$86.75M
2021-12-31-$83.53M$2.32M-$85.85M
2020-12-31-$46.18M$621,000.00-$46.8M
2019-12-31-$25.67M$780,000.00-$26.45M